NMR, HPLC, LCMS, COA, pls kindly check:
Name: SiponimodCAS NO.: 1230487-85-0, 1230487-00-9
Chemical Formula: C29H35F3N2O3
Exact Mass: 516.25998
Molecular Weight: 516.6
Elemental Analysis: C, 67.42; H, 6.83; F, 11.03; N, 5.42; O, 9.29
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
Harmonized System Code: 293490
2017 China CPHI: E1M35
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
労働時間: Beijing Time 4:00AM~11:00PM
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585
1: Safavi M, Nikfar S, Abdollahi M. A Systematic Review of Drugs in Late-Stage Development for the Treatment of Multiple Sclerosis: A Focus on Oral Synthetic Drugs. Inflamm Allergy Drug Targets. 2015;13(6):351-66. PubMed PMID: 26021323.
2: Briard E, Rudolph B, Desrayaud S, Krauser JA, Auberson YP. MS565: A SPECT Tracer for Evaluating the Brain Penetration of BAF312 (Siponimod). ChemMedChem. 2015 Jun;10(6):1008-18. doi: 10.1002/cmdc.201500115. Epub 2015 Apr 29. PubMed PMID: 25924727.
3: Ontaneda D, Fox RJ. Progressive multiple sclerosis. Curr Opin Neurol. 2015 Jun;28(3):237-43. doi: 10.1097/WCO.0000000000000195. PubMed PMID: 25887766; PubMed Central PMCID: PMC4425257.
4: Gonzalez-Cabrera PJ, Brown S, Studer SM, Rosen H. S1P signaling: new therapies and opportunities. F1000Prime Rep. 2014 Dec 1;6:109. doi: 10.12703/P6-109. eCollection 2014. Review. PubMed PMID: 25580263; PubMed Central PMCID: PMC4251414.
5: Yagi Y, Nakamura Y, Kitahara K, Harada T, Kato K, Ninomiya T, Cao X, Ohara H,
Izumi-Nakaseko H, Suzuki K, Ando K, Sugiyama A. Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation. Toxicol Appl Pharmacol. 2014 Sep 16;281(1):39-47. doi: 10.1016/j.taap.2014.09.006. [Epub ahead of print] PubMed PMID: 25223691.
6: Biswal S, Veldandi UK, Derne C, Golla G, Muhsen N, Legangneux E. Effect of oral siponimod (BAF312) on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in healthy female subjects. Int J Clin Pharmacol Ther. 2014 Nov;52(11):996-1004. doi: 10.5414/CP202142. PubMed PMID: 25161159.
7: Cree BA. 2014 multiple sclerosis therapeutic update. Neurohospitalist. 2014 Apr;4(2):63-5. doi: 10.1177/1941874414525410. PubMed PMID: 24707333; PubMed Central PMCID: PMC3975801.
8: Weiss HM, Gatlik E. Equilibrium gel filtration to measure plasma protein binding of very highly bound drugs. J Pharm Sci. 2014 Feb;103(2):752-9. doi: 10.1002/jps.23818. Epub 2013 Dec 20. PubMed PMID: 24375113.
9: Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke
F, Wallström E. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013 Aug;12(8):756-67. doi: 10.1016/S1474-4422(13)70102-9. Epub 2013 Jun
11. Erratum in: Lancet Neurol. 2013 Sep;12(9):846. PubMed PMID: 23764350.
